PARP inhibitors: the journey from research hypothesis to clinical approval

Personalized Medicine
Kishan At Naipal, Dik C van Gent

Abstract

Cancer puts an increasing burden on our healthcare system and is a major cause of death. Therefore, novel approaches are required to improve cancer treatment. Cancer cells have several hallmarks that could be therapeutically targeted. Importantly, every tumor has a different combination of aberrations affecting the different hallmarks. This review focuses on targeting one of these hallmarks, the DNA damage response (DDR). DDR defects can not only cause cancer, but they can also be exploited therapeutically. This plays an important role even in 'classical' (DNA damaging) chemotherapy and radiotherapy, but more precise targeting of specific defects is expected to increase treatment efficacy and decrease normal tissue toxicity. Poly-(ADP-ribose) polymerase (PARP) inhibitors are the first clinical example of such synthetic lethality in tumors having specific DDR defects. They are currently under investigation as DDR-targeting anticancer drugs and they progress quickly in clinical trials.

References

Apr 1, 1994·Trends in Biochemical Sciences·G de Murcia, J Ménissier de Murcia
May 22, 2003·Oncology·Susana M Campos, Eric P Winer
Oct 29, 2004·Nature Reviews. Cancer·Nicholas TurnerAlan Ashworth
Jun 7, 2006·Current Opinion in Pharmacology·Elizabeth Ruth Plummer
Jan 1, 2008·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Sven Rottenberg, Jos Jonkers
Feb 12, 2008·Nature·Stacey L EdwardsAlan Ashworth
Apr 17, 2008·Cancer Research·Elizabeth M SwisherToshiyasu Taniguchi
May 3, 2008·Cancer Research·I Bernard Weinstein, Andrew Joe
Dec 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ruth PlummerHilary Calvert
Apr 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shivaani KummarJames H Doroshow
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Apr 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Asima MukhopadhyayNicola J Curtin
May 11, 2010·Nature Structural & Molecular Biology·Peter BouwmanJos Jonkers
Jun 17, 2010·Cancer Research·Ponnari GottipatiThomas Helleday
Aug 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jurgen VeeckManel Esteller
Aug 31, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Monika GraeserNicholas C Turner
Oct 15, 2010·Science Translational Medicine·Konstantin J DedesJorge S Reis-Filho
Jan 7, 2011·The New England Journal of Medicine·Joyce O'ShaughnessyCharles Bradley
Jan 15, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ana M Gonzalez-AnguloFunda Meric-Bernstam
Feb 1, 2011·Journal of Molecular Cell Biology·Amal Aly, Shridar Ganesan
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
May 11, 2011·Proceedings of the National Academy of Sciences of the United States of America·Przemek M KrawczykJacob A Aten
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Jun 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Barbara NorquistElizabeth M Swisher
Jul 9, 2011·EMBO Reports·Sonja FlottStephen P Jackson
Sep 29, 2011·EMBO Molecular Medicine·Davide Torti, Livio Trusolino
Feb 1, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anand G PatelScott H Kaufmann
Feb 7, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shivaani KummarJames H Doroshow
Mar 1, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Arun RajanGiuseppe Giaccone
Mar 27, 2012·Molecular Cell·Samuel F BuntingAndré Nussenzweig

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02032823
NCT02000622
NCT01844986
NCT01874353
NCT01924533
NCT01968213
NCT01847274
NCT01945775
NCT02032277
NCT01905592

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Oncology : a Journal of the Royal College of Radiologists
Ruth Plummer
Cancer Science
Noriko Hosoya, Kiyoshi Miyagawa
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Elizabeth H StoverElizabeth M Swisher
Expert Opinion on Drug Discovery
Ahmed KamalMohammed Shaheer Malik
© 2022 Meta ULC. All rights reserved